Gut Microbiota-Based Immunotherapy: Engineered <i>Escherichia coli</i> Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.

ABSTRACT: Background and Objectives: The administration of oral vaccines offers a potential strategy for cancer immunotherapy; yet, the development of effective platforms continues to pose a difficulty. This study examines Escherichia coli Nissle 1917 (EcN) as a microbial vector for the precise delivery of Glypican-1 (GPC1), a tumor-associated antigen significantly overexpressed in pancreatic ductal adenocarcinoma (PDAC).To evaluate the effectiveness of EcN as a vector for the delivery of GPC1 and assess its potential as an oral vaccination platform for cancer immunotherapy. Materials and Methods: EcN was genetically modified to produce a GPC1-flagellin fusion protein (GPC1-FL) to augment antigen immunogenicity. The expression and stability of GPC1 were confirmed in modified PAN

SUBMITTER: Vruzhaj I 

PROVIDER: S-EPMC12028767 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature